BSE · 539206
Genomic Valley Biotech Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1 Cr with net profit ₹0 Cr — a 41.97% net margin, versus 9.11% the period before.
Shareholding
As of 2026-06-30
- Promoter46.06%
- Public53.94%
2,448 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.66× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0 · LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Miscellaneous · ranked #360 of 530 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Ports & Special Economic Zone Ltd. | ₹3,96,212 Cr | 119.01 | 4.12 | 13.32% | 33.06% |
| Eternal Limited | ₹3,00,898 Cr | 1641.05 | 9.25 | 1.18% | 0.67% |
| BSE Limited | ₹1,44,241 Cr | 183.02 | 21.65 | 37.42% | 51.66% |
| GAIL (India) Ltd. | ₹1,15,143 Cr | 77.49 | 1.29 | 8.51% | 5.34% |
| GMR Airports Limited | ₹1,13,087 Cr | 369.31 | — | -10.6% | 1.19% |
| Mazagon Dock Shipbuilders Ltd. | ₹93,092 Cr | 137.04 | 9.54 | 26.48% | 21.23% |
| One 97 Communications Ltd. | ₹85,211 Cr | 463.41 | 5.32 | 4.55% | 7.25% |
| Meesho Limited | ₹82,958 Cr | — | 18.88 | -28.13% | -8.68% |
| Info Edge (India) Ltd. | ₹80,913 Cr | 142.94 | 2.13 | 3.82% | 0.44% |
| Swiggy Limited | ₹79,315 Cr | — | 4.33 | -22.68% | -18.02% |
| Genomic Valley Biotech Limited(this company) | ₹9 Cr | 285 | 2.22 | 0.77% | 7.41% |
AI analysis
AI-generated · google/gemini-2.5-flashGenomic Valley Biotech Limited is listed on the Indian markets with a market capitalization of Rs 8 Cr. The company reported a P/E ratio of 272.6 and an EPS of 0.1. Its book value stands at Rs 12.85.
Positives
- +The debt-to-equity ratio is 0, indicating no debt.
- +Return on equity (ROE) is significantly high at 77.14%.
- +Net profit increased to Rs 0.3560932 Cr in Mar 2025 from Rs 0.0151818 Cr in Mar 2024.
Negatives
- −The company has a very high P/E ratio of 272.6.
- −The return on capital employed (ROCE) is relatively low at 1.0193%.
- −The company is under surveillance with both GSM and LT-ASM measures.
- −Promoter holding of 46.0632% is less than 50% as of June 30, 2026.
- −Quarterly revenue has declined from Rs 0.22 Cr in Dec 2024 to Rs 0.04 Cr in Mar 2026.
Financial Performance
Genomic Valley Biotech Limited reported revenue of Rs 0.8484054 Cr in Mar 2025, an increase from Rs 0.1665753 Cr in Mar 2024. Net profit also rose to Rs 0.3560932 Cr in Mar 2025, compared to Rs 0.0151818 Cr in Mar 2024. The company has shown fluctuating annual performance, with a net profit of -0.5590514 Cr in Mar 2021 and -0.0093402 Cr in Mar 2022, before recovering to positive figures.
Profitability & Returns
The company's profit margin was 7.41%. Return on equity (ROE) was reported at 77.14%, while return on capital employed (ROCE) was 1.0193%. The annual EBITDA for Mar 2025 was Rs 0.4414376 Cr.
Balance Sheet
Genomic Valley Biotech Limited has a debt-to-equity ratio of 0, indicating no outstanding debt. The book value per share is Rs 12.85. No other balance sheet figures are available for discussion.
Ownership & Pledges
As of June 30, 2026, promoters held 46.0632% of the company's shares. Public shareholding was 53.9368%. There were no shares pledged by the promoters. Institutional and FII holdings were 0%.
Regulatory & Surveillance
The company is currently under surveillance with measures including GSM and LT-ASM. This indicates heightened scrutiny from regulatory bodies.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Genomic Valley Biotech Limitedshare price & fundamentals